fbpx
June 5, 2023

FDA OKs Injectafer for Iron Deficiency Anemia in HF FDA OKs Injectafer for Iron Deficiency Anemia in HF

The US Food and Drug Administration (FDA) has expanded the indication for ferric carboxymaltose injection (Injectafer, Daiichi Sankyo/American Regent) to include treatment of iron deficiency in […]
June 5, 2023

Once-Weekly Growth Hormone Somapacitan Approved for Kids Once-Weekly Growth Hormone Somapacitan Approved for Kids

The once-weekly growth hormone analog somapacitan (Sogroya, Novo Nordisk) has been given the green light in both Europe and the United States for the treatment of children […]
June 1, 2023

UHC Ditches Prior Authorization in Favor of New Policy UHC Ditches Prior Authorization in Favor of New Policy

United Healthcare (UHC) has announced it will not go forward with a plan to require prior authorization for colonoscopies and other endoscopic procedures. Instead, the giant […]
June 1, 2023

FDA Approves Pfizer RSV Vaccine for Older Adults FDA Approves Pfizer RSV Vaccine for Older Adults

The US Food and Drug Administration (FDA) has approved another vaccine that protects adults older than 60 years from respiratory syncytial virus (RSV). Abrysvo, made by […]
June 1, 2023

Olaparib Gains BRCA-Mutated Prostate Cancer Indication Olaparib Gains BRCA-Mutated Prostate Cancer Indication

The US Food and Drug Administration (FDA) has approved olaparib (Lynparza, AstraZeneca) with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer, as determined […]
June 1, 2023

First IL-17 Inhibitor Approved in Europe for HS Patients First IL-17 Inhibitor Approved in Europe for HS Patients

The European Commission has approved secukinumab (Cosentyx) as a treatment for adults with active, moderate to severe hidradenitis suppurativa (HS) that didn’t respond to conventional therapy. […]
May 31, 2023

Posluma Approved for PET Imaging in Prostate Cancer Posluma Approved for PET Imaging in Prostate Cancer

The US Food and Drug Administration (FDA) has approved flotufolastat fluorine-18 (Posluma), a radiopharmaceutical for use with positron-emission tomography (PET) in prostate cancer. The product is […]
May 26, 2023

FDA Approves New Drug, Sotagliflozin, for Heart Failure FDA Approves New Drug, Sotagliflozin, for Heart Failure

Sotagliflozin, a novel agent that inhibits sodium-glucose cotransporter (SGLT) 1 as well as SGLT2, received marketing approval from the US Food and Drug Administration (FDA) on […]
May 24, 2023

FDA Approves Yuflyma as Ninth Adalimumab Biosimilar FDA Approves Yuflyma as Ninth Adalimumab Biosimilar

The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion, announced today. It is the […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0